Assessment of Echocardiography and Biomarkers for the Extended Prediction of Cardiotoxicity in Patients Treated With Anthracyclines, Taxanes, and Trastuzumab
暂无分享,去创建一个
Randolph P. Martin | E. Halpern | R. Gerszten | J. Plana | M. Picard | M. Scherrer-Crosbie | T. Tan | I. Kuter | B. Ky | J. Januzzi | J. Carver | J. Passeri | I. Sebag | S. Wiegers | J. Banchs | Heloisa Sawaya | V. Cohen
[1] Marc Buyse,et al. Adjuvant trastuzumab in HER2-positive breast cancer. , 2011, The New England journal of medicine.
[2] S. Manzano-Fernández,et al. Soluble ST2, high‐sensitivity troponin T‐ and N‐terminal pro‐B‐type natriuretic peptide: complementary role for risk stratification in acutely decompensated heart failure , 2011, European journal of heart failure.
[3] Pawan K. Singal,et al. The utility of cardiac biomarkers, tissue velocity and strain imaging, and cardiac magnetic resonance imaging in predicting early left ventricular dysfunction in patients with human epidermal growth factor receptor II-positive breast cancer treated with adjuvant trastuzumab therapy. , 2011, Journal of the American College of Cardiology.
[4] Randolph P. Martin,et al. Early detection and prediction of cardiotoxicity in chemotherapy-treated patients. , 2011, The American journal of cardiology.
[5] E. Winer,et al. Troponin I and C-Reactive Protein Are Commonly Detected in Patients with Breast Cancer Treated with Dose-Dense Chemotherapy Incorporating Trastuzumab and Lapatinib , 2011, Clinical Cancer Research.
[6] D. Grenache,et al. Establishment of reference intervals for soluble ST2 from a United States population. , 2010, Clinica chimica acta; international journal of clinical chemistry.
[7] F. Veglia,et al. Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] R. Coombes,et al. Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] T. Mueller,et al. Analytical and clinical evaluation of a novel high-sensitivity assay for measurement of soluble ST2 in human plasma--the Presage ST2 assay. , 2009, Clinica chimica acta; international journal of clinical chemistry.
[10] T. Marwick,et al. Use of myocardial deformation imaging to detect preclinical myocardial dysfunction before conventional measures in patients undergoing breast cancer treatment with trastuzumab. , 2009, American heart journal.
[11] F. Rademakers,et al. Strain rate imaging detects early cardiac effects of pegylated liposomal Doxorubicin as adjuvant therapy in elderly patients with breast cancer. , 2008, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.
[12] M. Guglin,et al. Trastuzumab-induced cardiomyopathy. , 2008, Journal of cardiac failure.
[13] J. Januzzi,et al. The differential diagnosis of an elevated amino-terminal pro-B-type natriuretic peptide level. , 2008, The American journal of cardiology.
[14] J. Bergh,et al. Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] Piet Claus,et al. Acute cardiac functional and morphological changes after Anthracycline infusions in children. , 2007, The American journal of cardiology.
[16] A. Weyman,et al. Tissue Doppler imaging predicts left ventricular dysfunction and mortality in a murine model of cardiac injury. , 2006, European heart journal.
[17] Greg Yothers,et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] V. Valero,et al. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] Richard D. White,et al. Mitral annular motion as a surrogate for left ventricular ejection fraction: real-time three-dimensional echocardiography and magnetic resonance imaging studies. , 2004, European journal of echocardiography : the journal of the Working Group on Echocardiography of the European Society of Cardiology.
[20] G. Martinelli,et al. Prognostic Value of Troponin I in Cardiac Risk Stratification of Cancer Patients Undergoing High-Dose Chemotherapy , 2004, Circulation.
[21] L. Gianni,et al. Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity , 2004, Pharmacological Reviews.
[22] D. Levy,et al. Natural History of Asymptomatic Left Ventricular Systolic Dysfunction in the Community , 2003, Circulation.
[23] J. Otterstad,et al. Measuring left ventricular volume and ejection fraction with the biplane Simpson’s method , 2002, Heart.
[24] B. Jensen,et al. Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.
[25] D. Sawyer,et al. Modulation of Anthracycline-Induced Myofibrillar Disarray in Rat Ventricular Myocytes by Neuregulin-1&bgr; and Anti-erbB2: Potential Mechanism for Trastuzumab-Induced Cardiotoxicity , 2002, Circulation.
[26] C. Hudis,et al. Cardiac dysfunction in the trastuzumab clinical trials experience. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.